Summary

Global Endometriosis Market, Analysis and Forecast: 2025-2035

Endometriosis is a chronic medical condition where tissue similar to the lining of the uterus (the endometrium) grows outside the uterus, causing pain, inflammation, and sometimes infertility. The abnormal growths, known as endometrial lesions, can be found on the ovaries, fallopian tubes, the outer surface of the uterus, and in other areas of the pelvic cavity. These growths respond to hormonal changes in the menstrual cycle, leading to bleeding, irritation, and pain, particularly during menstruation.

The endometriosis market is driven by rising prevalence and awareness, expanding treatment options, and growing focus on fertility preservation. As awareness about endometriosis increases, the number of diagnosed cases is rising. The condition is often underdiagnosed due to its symptoms being similar to other common conditions like irritable bowel syndrome (IBS) or pelvic inflammatory disease (PID). Better awareness and understanding of endometriosis are key drivers in the growth of the drug market. According to the American College of Obstetricians and Gynecologists, approximately 10% of women of reproductive age have endometriosis, translating to an estimated 190 million women worldwide.

Moreover, with advancements in imaging techniques, laparoscopy, and genetic markers, endometriosis is being diagnosed earlier. This leads to an increase in the patient population, thus driving the demand for treatments. A better diagnosis means patients are now seeking early intervention and management through drugs, which fosters market growth. Also, there has been a significant shift in treatment approaches, from traditional pain management (NSAIDs, hormonal therapies) to targeted therapies.

The average delay in diagnosing endometriosis is 7 to 10 years, primarily because its symptoms overlap with other conditions. This delay impacts treatment initiation and affects the progression of the disease and reduces the effectiveness of treatments. Furthermore, the lack of reliable non-invasive diagnostic tools (beyond laparoscopy) creates a barrier to early detection.

In addition, existing treatments, particularly hormonal therapies such as GnRH agonists, are effective but can lead to significant side effects, such as hot flashes, bone density loss, and mood swings. The need for long-term medication can result in poor adherence or switching to alternative therapies, limiting market potential. This presents a challenge for pharmaceutical companies to develop more effective treatments with fewer side effects. Furthermore, endometriosis treatment can be expensive, particularly for advanced therapies like surgery or biologics. Additionally, the cost of infertility treatments can be a financial burden. In low- and middle-income countries, access to appropriate care and medications remains a challenge.

The market for endometriosis is increasingly leaning toward targeted therapies. Future therapies are likely to target genetic mutations associated with endometriosis and endometrial tissue behavior, offering more effective treatments with fewer side effects.

As research continues to uncover the genetic and molecular mechanisms of endometriosis, there is a growing trend toward personalized treatment plans. This approach includes genetic testing and precision medicine that target specific molecular pathways involved in the disease process. Companies are focusing on precision medicine to develop therapies that work for individuals based on their genetic profiles.

Additionally, non-hormonal treatments present a significant opportunity to address the unmet need of patients who cannot tolerate or do not wish to use hormonal therapies. Drugs targeting pain pathways, inflammation, or vascularization of endometrial lesions could capture substantial market share.
With a growing number of women delaying childbirth, there is an increasing demand for fertility-sparing treatments for women with endometriosis. This includes medications that treat endometriosis without compromising fertility, such as GnRH antagonists, Danazol, and aromatase inhibitors. Companies investing in therapies that offer a balance between disease management and fertility preservation stand to benefit.

The competitive landscape of the endometriosis market is dominated by several key players, including both large pharmaceutical companies and biotech firms that are advancing innovative therapies.

ページTOPに戻る

Table of Contents

Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. Global Cystic Fibrosis Market: Industry Outlook
1.1 Market Overview
1.2 Epidemiological Analysis
1.3 Regulatory Landscape
1.4 Key Trends
1.5 Clinical Trial Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraint
1.6.4 Market Opportunities
2. Global Cystic Fibrosis Market, by Region, $Million, 2023-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Size and Forecast
2.1.2.1 North America Cystic Fibrosis Market, by Country
2.1.2.1.1 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Size and Forecast
2.2.2.1 Europe Cystic Fibrosis Market, by Country
2.2.2.1.1 Germany
2.2.2.1.2 U.K.
2.2.2.1.3 France
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Size and Forecast
2.3.2.1 Asia-Pacific Cystic Fibrosis Market, by Country
2.3.2.1.1 Japan
3. Global Cystic Fibrosis Market - Competitive Landscape and Company Profiles
3.1 Key Strategies and Developments by Company
3.1.1 Funding Activities
3.1.2 Mergers and Acquisitions
3.1.3 Regulatory Approvals
3.1.4 Partnerships, Collaborations, and Business Expansions
3.2 Company Profiles
3.2.1 Vertex Pharmaceuticals Incorporated
3.2.1.1 Overview
3.2.1.2 Product Portfolio
3.2.1.3 Target Customers
3.2.1.4 Key Personnel
3.2.1.5 Analyst View
3.2.2 Gilead Sciences, Inc
3.2.2.1 Overview
3.2.2.2 Product Portfolio
3.2.2.3 Target Customers
3.2.2.4 Key Personnel
3.2.2.5 Analyst View
3.2.3 Novartis AG
3.2.3.1 Overview
3.2.3.2 Product Portfolio
3.2.3.3 Target Customers
3.2.3.4 Key Personnel
3.2.3.5 Analyst View
3.2.4 Sumitomo Pharma (Spirovant Sciences, Inc.)
3.2.4.1 Overview
3.2.4.2 Product Portfolio
3.2.4.3 Target Customers
3.2.4.4 Key Personnel
3.2.4.5 Analyst View
3.2.5 Boehringer Ingelheim International GmbH
3.2.5.1 Overview
3.2.5.2 Product Portfolio
3.2.5.3 Target Customers
3.2.5.4 Key Personnel
3.2.5.5 Analyst View
3.2.6 Krystal Biotech, Inc.
3.2.6.1 Overview
3.2.6.2 Product Portfolio
3.2.6.3 Target Customers
3.2.6.4 Key Personnel
3.2.6.5 Analyst View
3.2.7 Others
4. Research Methodology

ページTOPに戻る

List of Tables/Graphs

List of Figures
Figure: Cystic Fibrosis Market (by Scenario), $Million, 2024, 2030, and 2035
Figure: Global Cystic Fibrosis Market, 2024 and 2035
Figure: Global Cystic Fibrosis Market Key Trends, Impact Analysis, 2023-2035
Figure: North America Cystic Fibrosis Market, $Million, 2023-2035
Figure: Europe Cystic Fibrosis Market, $Million, 2023-2035
Figure: Asia-Pacific Cystic Fibrosis Market, $Million, 2023-2035
List of Tables
Table: Market Snapshot
Table: Global Cystic Fibrosis Market, Market Dynamics, Impact Analysis
Table: Global Cystic Fibrosis Market (by Region), $Million, 2023-2035